


## ζ-Stat

<b>Cat. No.:</b>	HY-123979		
<b>CAS No.:</b>	3316-02-7		
<b>Molecular Formula:</b>	C <sub>10</sub> H <sub>8</sub> O <sub>10</sub> S <sub>3</sub>		
<b>Molecular Weight:</b>	384.36		
<b>Target:</b>	PKC; Apoptosis		
<b>Pathway:</b>	Epigenetics; TGF-beta/Smad; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 62.5 mg/mL (162.61 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	1 mM	2.6017 mL	13.0086 mL	26.0173 mL
	5 mM	0.5203 mL	2.6017 mL	5.2035 mL
	10 mM	0.2602 mL	1.3009 mL	2.6017 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (260.17 mM); Clear solution; Need ultrasonic			

## BIOLOGICAL ACTIVITY

<b>Description</b>	ζ-Stat (NSC37044) is a specific and atypical PKC-ζ inhibitor, with an IC <sub>50</sub> of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	aPKC-ζ 5 μM (IC <sub>50</sub> )
<b>In Vitro</b>	<p>ζ-Stat (0.1-20 μM) shows only 13% inhibition on PKC-ι at 20 μM, but shows a significant inhibition on PKC-ζ as 51% at 5 μM level<sup>[1]</sup>.</p> <p>ζ-Stat (0.1-10 μM; 3 d) significantly decreases cell proliferation of SK-MEL-2 and MeWo upon increasing the concentrations<sup>[1]</sup>.</p> <p>ζ-Stat (7 or 10 μM; 24-72 h) and 5-FU in combination is able to decrease the viability of LoVo CRC cells by more than 75%<sup>[2]</sup>.</p> <p>ζ-Stat (5 μM; 3 d) shows a significant diminution of phosphorylated, total PKC-ζ, Bcl-2 and PARP levels, and increases Caspase-3 and cleaved-PARP levels in SK-MEL-2 and MeWo cells<sup>[1]</sup>.</p>

ζ-Stat (5 μM; 1-10 h) does not show significant cytotoxicity on MEL-F-NEO, SK-MEL-2 and MeWo cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Proliferation Assay<sup>[1]</sup>

Cell Line:	MEL-F-NEO, SK-MEL-2 and MeWo cells
Concentration:	0.1, 0.5, 1, 2.5, 5, 7.5, 10 μM
Incubation Time:	3 days
Result:	Decreased proliferation by 47.7% for 5 μM in SK-MEL-2 cells and by 50.6% for 5 μM in MeWo cells. Showed significant inhibitions on MEL-F-NEO cells 19.3% (P ≤ 0.05) at 10 μM.

#### Western Blot Analysis<sup>[1]</sup>

Cell Line:	SK-MEL-2 and MeWo cells
Concentration:	5 μM
Incubation Time:	3 days
Result:	Decreased phosphorylated and total PKC-ζ levels.

## REFERENCES

[1]. Ratnayake WS, et, al. Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors. *Cell Adh Migr.* 2018; 12(5):447-463.

[2]. Islam SMA, et, al. Atypical Protein Kinase-C inhibitors exhibit a synergistic effect in facilitating DNA damaging effect of 5-fluorouracil in colorectal cancer cells. *Biomed Pharmacother.* 2020 Jan; 121:109665.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA